Neurocrine Biosciences acquires Soleno Therapeutics

Neurocrine Biosciences, Inc. is set to acquire Soleno Therapeutics, Inc. in a move that will bolster its foothold in the endocrinology and rare diseases sector. Valued at $2.9 billion, the acquisition grants Neurocrine control over Soleno's VYKAT XR (diazoxide choline), the only FDA-approved treatment for hyperphagia in Prader-Willi syndrome (PWS). This expansion is expected to enhance Neurocrine's portfolio, which already includes first-in-class therapies such as INGREZZA® and CRENESSITY®.

Under the terms of the agreement, Neurocrine will pay $53.00 per share in cash for Soleno, aiming to complete the acquisition by the second quarter of 2026. VYKAT XR, approved by the FDA and launched in the U.S. in 2025, generated $190 million in revenue during its debut year, testifying to its market potential and reception. The addition of this therapy is anticipated to drive Neurocrine's revenue and long-term growth, supported by its robust intellectual property estate projected to endure into the mid-2040s.

The strategic move is poised to leverage Neurocrine's established expertise in launching and marketing within its core sectors. According to Kyle W. Gano, Ph.D., CEO of Neurocrine Biosciences, the acquisition aligns with the company's mission to deliver transformative treatments and reflects a deepened commitment to the PWS community. Soleno's CEO, Anish Bhatnagar, emphasized that Neurocrine's commercial capabilities make it an ideal partner to extend the reach and impact of VYKAT XR, facilitating improved care for PWS patients.

The acquisition reflects broader dynamics in the biotechnology sector, as companies with strong commercial foundations seek to consolidate their position by acquiring innovative treatments in niche markets. With roughly 10,000 patients in the U.S. affected by PWS, which causes compulsive eating behaviors and significant health challenges, Neurocrine's acquisition positions it strategically within a distinct segment of rare diseases with unmet needs.

The transaction awaits customary closing conditions and regulatory approvals. Once completed, it could prompt other biotech firms to reevaluate their strategies in acquiring or developing first-in-class therapies to maintain competitive parity and expand in the high-growth domains of endocrinology and rare diseases.